Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. ONON
6. AAPL
7. TRMD
8. AZN
9. NVDA
10. RARE

Go back to Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
AGENUS (NASDAQ: AGEN) Delayed: 7.43 +0.21 (2.91%)
Previous Close $7.22    52 Week High $7.49 
Open $7.48    52 Week Low $2.61 
Day High $7.79    P/E N/A 
Day Low $7.33    EPS $-1.10 
Volume 518,739